Once-Daily Treatment for Mixed Anxiety/Depressive States: A Comparison of Slow Release Amitriptyline and Fluphenazine with Nortriptyline

1977 ◽  
Vol 5 (2) ◽  
pp. 109-113 ◽  
Author(s):  
R V Magnus ◽  
A A Schiff
Keyword(s):  
Side Effects ◽  
Sustained Release ◽  
Slow Release ◽  
Anxiolytic Effect ◽  
Daily Treatment ◽  
Dry Mouth ◽  
Double Blind ◽  
Once Daily ◽  
Therapeutic Advantage ◽  
Depressive States

Patients suffering from mixed anxiety/depressive states referred to a psychiatric out-patient clinic completed a four week course of either a once-daily tablet of 30 mg nortriptyline with 1· 5 mg fluphenazine, or a sustained release capsule of 50 mg amitriptyline once daily, on a double-blind basis. Depression improved satisfactorily on either treatment, but there was a greater reduction of anxiety on fluphenazine/nortriptyline. Drowsiness, however, occurred more frequently among the patients on amitriptyline, suggesting the sedative properties of this drug did not substitute adequately for a specific anxiolytic effect. Dry mouth was also noticeably more frequent with amitriptyline. As might be expected on pharmacokinetic and physiological grounds, the results suggest that the sustained release characteristics of the amitriptyline preparation lead to a maximization of side-effects during the day without conferring any therapeutic advantage.

Antihypertensive Efficacy and Safe Use of Once-Daily Sustained-Release Diltiazem in the Elderly: A Comparison with Captopril

1995 ◽  
Vol 23 (4) ◽  
pp. 244-253 ◽  
Author(s):  
J Nicaise ◽  
E Neveux ◽  
P Blondin ◽  
Keyword(s):  
Blood Pressure ◽  
Sustained Release ◽  
Diastolic Blood Pressure ◽  
Blood Pressure Reduction ◽  
The Elderly ◽  
Double Blind ◽  
Once Daily ◽  
Supine Diastolic Blood Pressure ◽  
Normal Limits ◽  
Electrocardiographic Parameters

The efficacy and safety of sustained-release diltiazem, 200 – 300 mg once daily was compared with that of captopril, 12.5 – 25 mg twice-daily, in 100 elderly patients (65 – 85 years old) with mild to moderate essential hypertension (supine diastolic blood pressure 95 – 115 mmHg). All patients received placebo for 2 weeks, followed by an 8-week double-blind period, and were randomized to either diltiazem ( n = 50) or captopril ( n = 50). Their blood pressure was measured at trough level at week 4 immediately before dosing, i.e. 24 h post diltiazem dose or 12 h post captopril dose. Also at week 4, in non-responders, diltiazem was increased from 200 to 300 mg once daily and captopril from 12.5 to 25 mg twice daily to achieve a target supine diastolic blood pressure reduction of at least 10 mmHg or a diastolic blood pressure below 90 mmHg. Supine diastolic blood pressure, at week 8, was significantly ( P < 0.001) reduced from 102 ± 1 to 90 ± 1 mmHg with diltiazem and from 103 ± 1 to 89 ± 1 mmHg with captopril, bringing this parameter within normal limits for both groups. Supine systolic blood pressure was also significantly ( P < 0.001) reduced. Target blood pressure was achieved in 68% of patients taking diltiazem and in 70% taking captopril. Distribution of adverse events was comparable in both groups; no significant changes in laboratory or electrocardiographic parameters occurred. Two serious events were reported with captopril: one sudden death and one cerebrovascular stroke. Sustained-release diltiazem once a day is a convenient, well tolerated, first line treatment for hypertension in the elderly, for whom the possibility of using two dose levels allows a close regimen adjustment, 200 mg being recommended as a starting dose.

No Effect Of Persantin On Platelet Aggregation And Plasma βTg Levels In Healthy Volunteers

1981 ◽  
Author(s):  
A W A Lensing ◽  
A Sturk ◽  
J W ten Cate
Keyword(s):  
Side Effects ◽  
Healthy Volunteers ◽  
Cerebrovascular Accident ◽  
Slow Release ◽  
Double Blind Study ◽  
Prolonged Administration ◽  
Double Blind ◽  
Normal Limits ◽  
Induced Aggregation ◽  
Release Form

Previous studies from our laboratory revealed no effect of aspirin on plasma βTG levels in healthy volunteers as well as in patients with cerebrovascular accident. This double blind study was undertaken to investigate the effect of prolonged administration of Persantin. Two groups of 10 volunteers each received 4×100 mg Persantin or 2×200 mg daily in slow release form for 21 days. Platelet studies were performed prior to- and once every week during the trial. The volunteers refrained from smoking and were not on oral contraceptives or other drugs. No effect was observed on ADP (1 μ M f.c.) or collagen induced aggregation. All βTG plasma levels were within normal limits i.e. below 60/ml of plasma. No tendency of decreasing levels was observed. Side effects were significantly more observed in the volunteers on slow release Persantin (Mean Whitney Test α < 0.025). Side effects included sensations of a dry mouth and thirst, headache and di2Lzyness.

Classic Migraine: Effective Prophylaxis with Metoprolol

Cephalalgia ◽  
1987 ◽  
Vol 7 (4) ◽  
pp. 231-238 ◽  
Author(s):  
P Kangasniemi ◽  
AR Andersen ◽  
PG Andersson ◽  
NE Gilhus ◽  
C Hedman ◽  
...  
Keyword(s):  
Slow Release ◽  
Global Rating ◽  
Prophylactic Effect ◽  
Double Blind ◽  
Once Daily ◽  
Total Frequency ◽  
Effective Prophylaxis ◽  
Better Than

Metoprolol slow-release tablets (Durules®), 200 mg, given once daily in the morning were compared with placebo in the prophylaxis of classic migraine. The trial comprised eight Scandinavian neurologic centres and was designed as a double-blind cross-over study with 4 weeks' run-in, four weeks washout, and 8 weeks of either treatment. Seventy-seven patients with two to eight migraine attacks per month were entered in the trial, and 73 completed it. A total of 1119 attacks with aura symptoms and 374 without were recorded. Metoprolol was significantly better than placebo with regard to the total frequency of attacks (1.8 versus 2.5 attacks/4 weeks), mean duration of attacks (6.0 versus 8.0 h/attack), mean global rating, and consumption of analgesics per attack: Similar differences could be shown for attacks with aura symptoms alone, except for the duration of attacks. Metoprolol is the first drug for which a prophylactic effect in classic migraine has been convincingly demonstrated.

scholarly journals Efficacy comparison of cetirizine and loratadine for allergic rhinitis in children

2012 ◽  
Vol 52 (2) ◽  
pp. 61
Author(s):  
Juliana Juliana ◽  
Rita Evalina ◽  
Lily Irsa ◽  
M. Sjabaroeddin Loebis
Keyword(s):  
Allergic Rhinitis ◽  
High Schools ◽  
Side Effects ◽  
Global Health ◽  
Treatment Effectiveness ◽  
Junior High Schools ◽  
Double Blind ◽  
Once Daily ◽  
Significant Difference ◽  
Therapeutic Responses

Background Allergic rhinitis represents a global health problemaffecting 10% to more than 40% of the population worldwide.Several studies in recent years have described the efficacy ofsecond-generation antihistamines in younger children. It isnot well established whether cetirizine is more effective thanloratadine in reducing symptoms of allergic rhinitis.Objective The objective of this study was to compare the efficacyof loratadine with cetirizine for treatment of allergic rhinitis.Methods We conducted a randomized, double-blind, controlledtrial of 100 children, aged 13 to 16 years, from October toNovember 2009 at two junior high schools in Medan. GroupI received 10 mg of cetirizine and group II received 10 mg ofloratadine, each once daily in the morning for 14 days. Drugefficacy was assessed by changes from baseline symptom scoresand evaluation of therapeutic responses after 3 days, 7 days and14 days of treatment.Results The efficacy of cetirizine compared to that of loratadinewas not statistically significant in diminishing nasal symptomsafter 3 days, 7 days and 14 days of treatment (P=0.40, P=0.07,and P=0.057, respectively). Evaluation of side effects, however,revealed significantly fewer headaches in the cetirizine group after3 days and 7 days of treatment (P=0.01 and P=0.03, respectively)than in the loratidine group. In addition, the loratadine grouphad significantly more instances of palpitations after 7 days oftreatment (P=0.04) compared to the cetirizine group.Conclusion There was no significant difference in cetirizine andloratadine treatment effectiveness on allergic rhinitis. However,loratadine was found to cause more headaches and palpitationsthan cetirizine. [Paediatr lndones. 2012;52:61-6].

Sign in / Sign up

Export Citation Format

Share Document